World Gin Day 2019: Cannabis with your Gin?
Published 11-JUN-2019 12:50 P.M.
3 minute read
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Saturday was World Gin Day — a global celebration of all things gin.
Always on the second Saturday in June, World Gin Day is now in its tenth year. The idea is simple and pretty straight forward (as explained by the organised Emma Stokes, aka Gin Monkey): “get people together all around the world with a legitimate excuse to drink some gin”.
But rather than going for the standard G&T, it might be time to live a little and try out some of the more interesting gin varieties...
In what might be peak gin culture, one local Melbourne business, The Cannabis Company, which sells a range of hemp-derived products for both humans and pets, is getting in on the action as the “first in the world to distil hemp gin using cannabis terpenes”.
The Cannabis Company sells three cannabis-infused gins: The Myrcene – the world's first cannabis-infused gin distilled with terpenes; Jilyngin Dreaming – a cannabis-terpene hemp gin distilled with native Australian botanicals; and High Seas – navy strength (116 proof) gin.
I asked Finfeed’s in-house gin connoisseur, Chris A, for his expert opinion. While he hasn’t yet tried it himself, his expectations are tempered: “I was talking to a bar tender the other night about it and he was saying it’s basically a gimmick. Hemp doesn’t have that much flavour in it to really make a difference. That being said I’d like to try it but won’t be rushing out to buy a bottle anytime soon.”
(He, for what it’s worth, personally likes dry gins – Never Never Juniper Freak, Prohibition Gin, Patient Wolf Melbourne Dry).
But maybe this focus on the taste is missing the point entirely.
The Cannabis Company claim when you ingest cannabis together with terpenes, you get a synergistic and uniquely positive effect. It says, “People are coming back to us with mad claims – it’s improved their sleep, it keeps them calm, it even cures the symptoms of their fibromyalgia.”
Here’s one such claim:
“Hi guys, I just wanted to write to you because my friends are all telling me that I’m mental. I don’t know if this is a placebo effect or what, but it seems that when I drink your gin either before or after smoking weed, I get about 30% more stoned!? Am I imagining this? I know you do the whole scientific thing so what’s the go?”
The go, according to the Cannabis Co., is that when the terpene myrcene is present in your bloodsteam and you ingest cannabis, it acts as an express receptor. You receive the cannabinoids from the cannabis faster, and it acts longer.
The terpene Myrcene is known as an anti-bacterial, anti-diabetic, anti-inflammatory, anti-insomniatic, anti-proliferative, antipsychotic, and anti-spasmodic. Cannabinoids have been demonstrated to absorb more efficiently into the blood brain barrier when terpenes are present, allowing them to bind to receptors in the endocannabinoid system.
So when the terpene myrcene is present in your bloodstream and you ingest cannabis, it acts as an express receptor. You receive the cannabinoids from the cannabis faster, and it acts longer.
So basically, it will help you get high (which, by the way, is not yet legal in Australia).
On the topic of cannabis, ASX-listed medicinal cannabis company Creso Pharma (ASX: CPH) delivered shareholders with some welcome news yesterday.
The company received a A$122 million takeover offer from Canadian cannabis company PharmaCielo Limited (TSXV:PCLO), the largest cannabis producer in Colombia.
This offer to $0.63 per share — a 50% premium to CPH’s Thursday closing price.
Cheers to that.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.